MENTHOLATUM PICKING UP 11 OTC PRODUCTS FROM STERLING, the two firms announced Sept. 17. Sterling said the sale of trademark rights and inventories of the products "is consistent with Sterling's announced policy to concentrate on businesses and product lines in which it has substantial market positions and which fit best with the company's long-term goals." The drugs involved in the sae include several laxatives such as Fletcher's Castoria, the pain reliever Cope, Caroid tooth powder, Medi-Quik first-aid spray, Cremalin antacid tabs and Fizrin analgesic-antacid. Sterling will send letters to the trade announcing the sale after completion of the transaction, which the company said is scheduled for early October. Sterling also recently agreed to sell its Givenchy fragrance unit to Paris-based Givenchy, S.A. Sterling will continue to produce the products for two years, at which time Mentholatum will take over production. The purchase from Sterling will double Mentholatum's OTC line to 22 in terms of number of products. The Buffalo, N.Y.-based firm currently markets 11 OTC products, including the Mentholatum line, Resicort Cream and Resinol Ointment.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Clinical trial sponsors in the rare disease space face “big safety demands” from regulators, which can be challenging for those with limited resources. A CRO founder makes the case for “embedding automation” into the clinical trial process to keep pace with regulatory requirements.
The developers of the ChAdOx1 NipahB vaccine will be able to benefit from the early and enhanced support that the European Medicines Agency offers through its priority medicines scheme.
The termination of the HHS Secretary’s Committee on Human Research Protections closed an important forum for discussing pediatrics and pregnancy in clinical trial design, a former SACHRP chair said.
